Completed drafting packet · October 18, 2026
Losartan
AI-assisted draft, not yet reviewed
Explore the expanded explanation and evidence prepared for this medicine. This review edition is separate from the current visual guide.
Open the current guide and visual story →
Choose your perspective
Each view has its own explanation. Some older-page packets contain targeted FAQ repairs only; those are identified below.
Patient
Losartan blocks AT1, a switch that a hormone uses to squeeze blood vessels. Your body also makes an active form, EXP3174 (E-3174), which helps block it. Vessels relax, and kidney salt signals change. Blood pressure starts to fall within a week; the full effect can take 3–6 weeks. Blood tests check kidney function and potassium, a salt in the blood. The boxed warning says it can harm or kill an unborn baby. The label also rules out use after allergy to its contents, or with aliskiren in people with diabetes. Ask your care team about these risks.
Limits: Educational draft; individual treatment and final clinical review require a qualified professional.
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
patient-05 — How will I know whether it is helping?
Established. A series of blood-pressure readings shows more than how you feel after one pill. Losartan starts to lower pressure within a week, with the full effect often reached in 3–6 weeks. Keep the record your care team has asked for and bring it to the next visit. For some people with diabetes and kidney disease, the team also tracks urine protein and kidney health over time. Ask which treatment goal applies to you. One high reading is not a reason to change the dose yourself.
Sources: LABEL
patient-18 — Will I need tests or monitoring?
Established. Blood tests check potassium, a salt in the blood, and creatinine, a sign of kidney function. These checks look for risks that you may not feel. For people with chronic kidney disease, KDIGO guidance calls for checks within 2–4 weeks after starting or raising a dose, with timing based on risk. Your care team sets your schedule. Report poor fluid intake, vomiting, diarrhea or new pain pills such as ibuprofen. These can change kidney risk even when the blood-pressure readings look good.
Caregiver
Losartan and its active form, EXP3174 (E-3174), block AT1 switches in blood vessels, kidneys and the adrenal glands. This lowers blood pressure over weeks. Keep a record of readings, falls, poor intake and new medicines. Ask the pharmacist about pain pills such as ibuprofen and salt substitutes that contain potassium. Cozaar contains losartan; Hyzaar adds a water pill. Check the full name to avoid mix-ups. The boxed warning says losartan can harm or kill an unborn baby. Ask the care team for an illness plan if the person cannot keep fluids down.
Limits: Educational draft; individual treatment and final clinical review require a qualified professional.
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
caregiver-11 — How can I help with an inhaler or other device?
Established. Losartan tablets are swallowed; they do not use an inhaler or injection pen. A prescribed liquid does need a medicine measure. Ask the pharmacist to show the dose on an oral syringe and check the strength in milligrams per milliliter. A kitchen spoon is not a safe measure. The label describes one compounded liquid that needs shaking and cold storage. Check the instructions on the actual bottle, because a different liquid may have different rules. Ask the person to show the steps back to you.
recalls — What do past recalls mean for a refill today?
Established. Past losartan recalls involved specific products and lots with unwanted chemicals called nitrosamines. They did not mean that every losartan tablet was recalled. Keep the bottle so the pharmacist can check its maker and lot number against current FDA notices. Ask how to get a replacement if that exact supply is affected. A past recall does not show whether a new bottle is affected today. Report a refill problem early so the care team can help keep the treatment plan on track.
Pharmacist
Losartan and EXP3174 (E-3174) block vascular, adrenal and renal AT1 signaling to lower pressure. About 14% of an oral dose forms this active metabolite,10–40 times more potent by weight, with 6–9-hour half-life. Human interaction data primarily implicate CYP2C9: fluconazole lowers metabolite exposure and rifampin lowers both exposures. Reconcile potassium, NSAIDs, lithium and dual RAS blockade; URAT1-linked uricosuria is a selection consideration, not gout treatment. The boxed warning concerns fetal toxicity; hypersensitivity and aliskiren coadministration in diabetes are contraindications. Check volume depletion, hepatic impairment and formulation-specific suspension storage against the label.
Limits: Educational draft; individual treatment and final clinical review require a qualified professional.
Questions for this perspective
5 drafted questions in this packet. Targeted additions or replacements for the current guide.
pharmacist-04 — What adjustments apply in renal or hepatic impairment?
Established. Cozaar specifies a 25 mg starting dose for mild-to-moderate hepatic impairment; severe hepatic impairment has not been studied. Mild-to-moderate renal impairment increases parent and metabolite exposure, but renal impairment alone does not automatically dictate a lower initial dose. Volume depletion changes that assessment and has a 25 mg start in the label. Neither parent nor metabolite is removed by hemodialysis. Reconcile indication, pressure, volume status, potassium and creatinine instead of using estimated filtration as a stand-alone dosing rule. Pediatric renal restrictions are separate.
Sources: LABEL
pharmacist-06 — Which drug interactions are important?
Established. Fluconazole reduces active-metabolite AUC by about 40% while increasing parent exposure; rifampin reduces both parent and metabolite AUC. Human interaction findings primarily support CYP2C9-mediated activation, despite in-vitro CYP 3 A 4 involvement. Pharmacodynamic risks often matter more: potassium-raising agents can increase hyperkalemia; NSAIDs can impair renal function and reduce antihypertensive effect, especially with volume depletion or diuretics. Lithium concentrations can rise. Dual RAS blockade increases hypotension, renal and potassium risks; aliskiren with losartan is contraindicated in diabetes. The label does not prescribe a universal compensatory dose change for CYP interactions.
Sources: LABEL
pharmacist-09 — What baseline and follow-up monitoring is needed?
Established. Establish pressure, creatinine/eGFR, potassium, volume status, pregnancy plans and interacting medicines. KDIGO 2024 recommends BP, creatinine and potassium checks within 2–4 weeks of starting or increasing a RAS inhibitor, adjusted for current GFR and potassium. Its continuation practice point uses a creatinine rise greater than 30% within four weeks as an evaluation threshold, not permission to ignore symptoms or acute injury below that percentage. Investigate volume loss, NSAIDs and other causes. Arrange a clear escalation and follow-up plan rather than an unqualified acceptable-rise rule.
pharmacist-17 — What preparation, storage and stability rules apply?
Established. Cozaar§2.5 specifies a 200 mL,2.5 mg/mL suspension prepared from ten 50 mg tablets,10 mL purified water and 190 mL of a 50:50 Ora-Plus/Ora-Sweet SF mixture in an amber PET bottle. It prescribes staged shaking and a one-hour standing interval; use the full procedure rather than this ingredient summary. The specified suspension is refrigerated at 2–8°C for up to four weeks, shaken before each use and returned promptly to refrigeration. These conditions do not validate another vehicle, container, concentration or feeding-tube method. Confirm pharmacy preparation and the dispensed beyond-use instructions.
Sources: LABEL
urate — Does urate lowering distinguish losartan?
Established. Losartan inhibits URAT1-linked renal urate reabsorption and has small human studies showing uricosuria and lower serum urate. In a 13-person crossover study of hypertension with hyperuricemia and gout, losartan lowered urate whereas irbesartan did not. This can inform selection among otherwise suitable antihypertensive options, but it is not evidence that losartan replaces established gout treatment. Do not claim every other ARB lacks URAT1 activity: telmisartan inhibited the transporter in an experimental system. Keep transport assays, serum-urate outcomes and gout-flare outcomes distinct.
Clinician
Losartan and EXP3174 (E-3174) antagonize vascular, adrenal and renal AT1 signaling. In RENAAL, the renal/death composite occurred in 327/751 versus 359/762 over mean 3.4 years; mortality alone was not reduced. LIFE primary events were 508/4605 versus 588/4588 over 4.8 years; stroke counts 232 versus 309 have the label’s Black-patient limitation. ELITE II (1578 versus 1574) did not establish mortality superiority over captopril;2022 HF guidance conditions ARB use on ACE intolerance and ARNI infeasibility. KDIGO 2024 guides albuminuric CKD treatment and monitoring. URAT1-related urate lowering informs comorbidity discussion, not gout substitution. Boxed fetal toxicity, hypersensitivity and aliskiren with diabetes require explicit screening.
Limits: Full trial denominators, follow-up, subgroup wording and guideline conditions appear in05; no patient-specific treatment recommendation.
Sources: LABEL; RENAAL; LIFE; ELITE2; HF; KDIGO; URAT; URATECLIN
Questions for this perspective
5 drafted questions in this packet. Targeted additions or replacements for the current guide.
clinician-01 — Where does this drug fit in treatment?
Established. The 2025 US and 2024 ESC hypertension guidelines include ARBs among first-line drug classes. KDIGO 2024 recommends ACEi or ARB treatment for defined albuminuric CKD groups, using the highest approved tolerated dose with monitoring. For chronic HFrEF,2022 AHA/ACC/HFSA guidance recommends an ARB when ACE inhibition is not tolerated because of cough or angioedema and ARNI is not feasible; ARNI has a preferred role in eligible symptomatic HFrEF. These recommendations do not add a US Cozaar heart-failure indication. Match guideline context to the selected product label and population.
Sources: USHTN; ESC; KDIGO; HF; LABEL
clinician-04 — How large is the absolute clinical benefit?
Established. RENAAL enrolled 1513 participants with type 2 diabetes and nephropathy. Over mean 3.4 years, the primary composite occurred in 327/751 on losartan versus 359/762 on placebo-based care: a crude absolute difference of 3.571 percentage points. Its reciprocal is 28.004, approximately 28; strict upward integer rounding yields 29. This descriptive count-based calculation differs from the reported time-to-event 16% relative reduction and does not imply a mortality benefit. In LIFE, stroke occurred in 232/4605 versus 309/4588 over mean 4.8 years, a 1.697-point crude difference, with the label’s population and subgroup limits.
Sources: RENAAL; LIFE; CANADA; LABEL
clinician-06 — How applicable is LIFE to another population?
Established. LIFE studied 9193 adults aged 55–80 with hypertension and ECG-defined left-ventricular hypertrophy, comparing losartan-based with atenolol-based regimens, commonly with hydrochlorothiazide. It did not compare all contemporary first-line choices. Final blood pressures were similar but not equal. The label states that evidence indicates the stroke-risk benefit does not apply to Black patients: the primary composite was 46/270 versus 29/263 in that subgroup. This finding limits the supported outcome claim; it is not a race-based contraindication or proof about every losartan indication.
clinician-03 — What did ELITE and ELITE II establish?
Established. ELITE enrolled 722 older patients with HFrEF and found the same 10.5% primary persistent-creatinine-rise rate in both groups. Its unexpected mortality signal was exploratory. ELITE II then randomized 1578 participants to losartan and 1574 to captopril; median follow-up was 555 days. Average annual mortality was 11.7% versus 10.4%, hazard ratio 1.13 with 95.7%CI 0.95–1.35, without significant superiority. Losartan had fewer adverse-effect withdrawals. Do not convert annual mortality rates into cumulative NNT or interpret this superiority trial as proof of equivalence. Current HF placement requires the guideline as well as historical trials.
clinician-13 — How do comorbidities affect the choice?
Established. Albuminuric diabetic CKD is a strong evidence context for RAS blockade, with Cozaar’s labeled nephropathy population narrower than every patient with diabetes. Hyperuricemia may favor discussion of losartan’s urate-lowering action when blood-pressure options are otherwise suitable; the small comparative evidence is biochemical, not proof of fewer gout attacks. Pregnancy carries boxed fetal toxicity. Review potassium, renal perfusion, volume depletion and aliskiren in diabetes before selection. A urate advantage does not override these risks, and a creatinine change must be interpreted with the full clinical course.
Nurse
Losartan and EXP3174 (E-3174) block AT1 responses in vessels, adrenal glands and kidneys. Lower aldosterone can raise potassium; altered kidney filtration pressure can raise creatinine. Pressure reduction starts within a week and develops over 3–6 weeks. Check ordered blood-pressure parameters, fluid status, kidney results and potassium, particularly after illness or treatment changes. The boxed warning identifies fetal injury or death; flag pregnancy promptly. Hypersensitivity and aliskiren use in diabetes are contraindications. Teach-back should confirm why blood tests matter and whom to call if vomiting prevents fluid intake.
Limits: Educational draft; individual treatment and final clinical review require a qualified professional.
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
nurse-07 — Are dilution, infusion or compatibility checks relevant?
Established. Cozaar is an oral tablet product, with a specific compounded oral suspension described in its label. Intravenous dilution, infusion-rate and line-compatibility instructions do not apply to this product. Oral liquid preparation and administration still require concentration, measuring-device, shaking and storage checks. Do not interpret not-applicable infusion checks as permission to improvise a liquid or administer it through a tube. Ask pharmacy to confirm the actual formulation and route, and use the prescribed administration record and local procedure for any unresolved discrepancy.
Sources: LABEL
nurse-18 — What should teach-back check?
Established. Ask the patient to explain what blood-pressure readings show and why potassium and kidney blood tests are needed even without symptoms. Confirm the agreed contact plan for vomiting, diarrhea, poor intake, faintness or reduced urine, and identify OTC NSAID or potassium-salt use. The boxed warning requires urgent pregnancy recognition and prescriber contact; the label calls for discontinuation as soon as pregnancy is detected. Hypersensitivity and aliskiren use in diabetes must be flagged. Use the actual prescription and local escalation process rather than inventing universal hold thresholds.
Student
Losartan and EXP3174 (E-3174) antagonize AT1 receptors in vascular smooth muscle, adrenal tissue and the kidney. Blocking Gq/11–PLC–IP3/Ca2+ signaling reduces contraction; less aldosterone changes sodium and potassium handling, while efferent arteriolar effects alter filtration pressure. Blood pressure falls over weeks. Renin and angiotensin II rise through feedback even during effective blockade; AT2 remains available. Parent losartan is active, whereas the metabolite has greater functional potency and a 6–9-hour half-life. Reversible insurmountable antagonism in an experiment does not mean covalent binding or prove clinical superiority over another ARB.
Limits: Educational draft; individual treatment and final clinical review require a qualified professional.
Questions for this perspective
5 drafted questions in this packet. Targeted additions or replacements for the current guide.
student-03 — How does AT1 blockade lower pressure?
Established. Angiotensin II activates AT1 receptors on vascular smooth muscle, including Gq/11–PLC signaling that generates IP3 and mobilizes calcium for contraction. Losartan and EXP3174 (E-3174) inhibit that receptor response. Adrenal aldosterone signaling and kidney hemodynamics also change, connecting receptor action to sodium handling, potassium risk and filtration pressure. This is a selected pathway diagram, not every AT1 signal: the cited smooth-muscle study distinguished early PLCβ and later PLCγ responses. Mechanistic plausibility explains what to measure; clinical outcome trials establish whether a treatment strategy helps a defined population.
student-05 — Which PK facts explain the time course?
Established. Losartan has about 33% oral bioavailability and reaches peak concentrations around one hour; its active metabolite peaks at 3–4 hours. Parent and metabolite half-lives are approximately 2 hours and 6–9 hours, respectively. About 14% of the oral dose becomes the active metabolite, whose exposure is about four times parent exposure. These values help explain why parent half-life alone cannot predict treatment duration. The label reports a substantial blood-pressure effect within a week and maximal effect over 3–6 weeks. Plasma peaks, receptor effects and chronic clinical response are different measurements.
Sources: LABEL
student-08 — Is losartan an inactive prodrug?
Established. No. Losartan itself competitively and reversibly antagonizes AT1 receptors. Metabolism also produces EXP3174 (E-3174), a more potent active carboxylic acid metabolite with longer half-life. The label describes reversible noncompetitive functional behavior for the metabolite; that is not evidence of covalent binding. Candesartan cilexetil and olmesartan medoxomil provide different examples: ester prodrugs converted to active ARBs. Distinguish a drug that is active before metabolism from one designed for conversion, and do not treat greater receptor potency as an equivalent multiplier of clinical benefit.
Sources: LABEL; METAB; COMPARATORS
student-10 — Which adverse effects follow from the mechanism?
Established. Less aldosterone can reduce renal potassium excretion, raising serum potassium. Reduced angiotensin-dependent filtration pressure can worsen kidney function in susceptible settings, especially volume depletion or renal artery disease. Less vasoconstriction can cause symptomatic hypotension. Fetal renin–angiotensin signaling is also affected, explaining the boxed warning. Losartan does not directly inhibit ACE-mediated bradykinin degradation, so ACE-inhibitor cough is less characteristic, but cough and angioedema are not impossible. The potassium counterion contributes little potassium per tablet; the major hyperkalemia mechanism is hormonal and renal physiology.
student-15 — Why can renin rise while treatment works?
Established. AT1 blockade removes part of the feedback that normally restrains renin release. The label reports a two-to-threefold rise in plasma renin activity with resulting higher angiotensin II levels during treatment. Higher upstream hormone levels therefore do not alone demonstrate failure of receptor blockade. AT2 receptors remain available, but attributing a particular clinical outcome to unopposed AT2 signaling requires evidence beyond this feedback observation. Compare losartan with lisinopril at the pathway level: receptor antagonism and ACE inhibition interrupt different steps and have different bradykinin consequences.
Sources: LABEL
Scientist
Losartan and EXP3174 (E-3174) antagonize AT1 signaling in vascular, adrenal and renal tissues, lowering blood pressure. Established evidence includes label pharmacology, LIFE/RENAAL outcomes and the engineered losartan-bound 9ZXC structure in Skiba 2026. URAT1 inhibition and small human studies support a separate uricosuric action. Probable contribution of persistent metabolite activity to duration is distinct from proving that one functional antagonism assay explains the clinical effect. Uncertain clinical contribution of unopposed AT2 signaling remains a testable question. The 3.4Å entry uses a nanobody-stabilized construct, not an unmodified receptor in a living kidney.
Limits: Model resolution, construct engineering and functional assay conditions limit native-receptor inference.
Sources: LABEL; METAB; STRUCT; LIFE; RENAAL; URAT; URATECLIN
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
structure — What does the losartan-bound structure establish?
Established. PDB 9ZXC places losartan, ligand LSN, in an engineered AT1 receptor complex stabilized with nanobody AT118-R. The entry reports 3.4Å cryo-EM resolution; the 2026 paper describes 3.3Å for the losartan complex. The paper’s main focus is a nonpeptide agonist, with losartan providing antagonist comparison. This is not an unmodified native receptor in a living tissue. Prior 2024 work already included a losartan-bound AT118-L complex. A static structure supports binding-site interpretation but cannot establish clinical residence time, whole-body occupancy or outcome superiority.
Sources: STRUCT; PRIORSTRUCT
urat — How would the URAT1 mechanism be tested separately?
Established. URAT1 transport assays and small human urate studies support an action distinct from AT1-mediated pressure reduction. Iwanaga’s oocyte experiments show substrate-side and preloading conditions matter, and telmisartan also inhibits URAT1 in vitro. Hamada’s study linked losartan response to functional URAT1, including patients with loss-of-function variants. A proposed follow-up should measure unbound parent and metabolite exposure, urate transport and AT1 signaling separately, with transporter-negative controls and rescue. This is a research design proposal, not a validated assay protocol or evidence that all serum-urate change is transporter-specific.
Chemist
Losartan potassium combines an acidic biphenyl tetrazole with a 2-butyl-4-chloro-imidazole bearing a 5-hydroxymethyl group. Oxidation yields the carboxylic acid EXP3174 (E-3174), alongside an already active parent. Both antagonize AT1 in vessels, adrenal glands and kidneys, lowering pressure. Duncia/Carini SAR supports the ortho acidic group and lipophilic substituents; current human interaction data primarily implicate CYP2C9 in metabolite formation. Skiba 2026 and PDB 9ZXC place ligand LSN in an engineered receptor complex at 3.4Å. The potassium counterion describes the salt; elevated serum potassium follows chiefly from altered renal hormonal physiology.
Limits: Coordinate distances alone do not establish hydrogen bonds, physiological protonation or binding free energy.
Questions for this perspective
2 drafted questions in this packet. Targeted additions or replacements for the current guide.
chemist-04 — What did the original SAR establish?
Established. Duncia’s nonpeptide antagonist work identified the value of an additional aromatic ring, an appropriately placed acidic group, a lipophilic imidazole substituent and a hydrogen-bonding group. Carini’s series supported an ortho acidic group and tetrazole as an effective isostere, leading to DuP 753. Losartan’s 5-hydroxymethyl group is oxidized to the active carboxylic acid metabolite. These are measured series-level observations, not proof that each substitution independently improves clinical outcomes. Interpret them with exposure, selectivity and the engineered 9ZXC binding model rather than drawing a clinical potency ladder from structure alone.
chemist-10 — Which transporter claim is supported?
Established. URAT1 is a supported pharmacodynamic off-target for parent losartan’s uricosuric action. This does not mean URAT1 controls systemic losartan clearance or explains all its drug interactions. Transport studies distinguish parent from EXP3174 (E-3174), and experimental inhibition depends on concentration and membrane-side conditions. Human urate data strengthen the biological link but do not supply a complete disposition model. Separate a drug acting on a transporter from a drug being transported by it; renal excretion percentages alone establish neither substrate identity nor the quantitative contribution to clearance.
Investor / Diligence Analyst
Losartan and EXP3174 (E-3174) block vascular, adrenal and renal AT1 signaling, supporting a mature blood-pressure franchise. LIFE primary events were 508/4605 versus 588/4588 over 4.8 years; RENAAL 327/751 versus 359/762 over 3.4 years. ELITE II (1578 versus 1574) did not prove mortality superiority. ClinCalc estimates 59.0 million US prescriptions,15.4 million patients and rank 7 in 2024. Teva announced generic approval in 2010. Historical nitrosamine recalls make manufacturer and lot controls material diligence questions. Valsartan, olmesartan and telmisartan compete within the class; sacubitril/valsartan occupies a different HF evidence position. Next checks are current Orange Book entries, payer data and supply records, not an assumed price or exclusivity premium.
Limits: Utilization is a survey estimate, not revenue. [VERIFY: market, generic-entry and current supply/IP facts before publication.]
Sources: LABEL; LIFE; RENAAL; ELITE2; VOLUME; GENERIC; RECALL; HF
Questions for this perspective
7 drafted questions in this packet. Targeted additions or replacements for the current guide.
analyst-03 — How large is the reachable patient market?
Established. ClinCalc estimates 59,030,486 US losartan prescriptions and 15,388,926 patients in 2024, ranking it seventh by prescription volume. These MEPS-derived estimates describe historical utilization, not unique worldwide patients, eligible untreated demand or company revenue. A reachable market model needs a defined product and indication, geography, payer coverage, net price, switching friction and overlap with other treatments. Use the published counts as a demand signal, then build an explicitly sourced funnel. Do not multiply prescriptions by a retail listing and call the result a defensible market size.
analyst-06 — How strong is the clinical outcome evidence?
Established. LIFE recorded primary events in 508/4605 on losartan-based versus 588/4588 on atenolol-based treatment over mean 4.8 years; stroke counts were 232 versus 309. RENAAL recorded the renal/death composite in 327/751 versus 359/762 over mean 3.4 years, without an all-cause mortality reduction. ELITE II randomized 1578 versus 1574 and did not establish mortality superiority over captopril. These are credible randomized outcome programs with different populations, comparators and endpoints. They validate specific claims, not a blanket efficacy premium across every cardiovascular indication. The detailed trial cards preserve adjusted effects, absolute differences and label limitations.
Sources: LIFE; RENAAL; ELITE2; CANADA; LABEL
analyst-12 — What are the next decisive development milestones?
Established. For established generic losartan, a sensible diligence milestone is confirmation of the exact proposed product, current approval holder, formulation and commercial route. A new indication or formulation needs its own target product profile, evidence gap and regulatory discussion; historical LIFE or RENAAL results do not automatically support it. Next evidence should connect the claimed differentiation to a prespecified clinical or formulation endpoint and a feasible manufacturing plan. No sponsor or new program has been selected here, so a calendar launch forecast would be invented.
analyst-15 — What capital and time would a new program require?
Established. A budget depends on whether the proposal is generic supply, a new formulation or a new indication. Losartan’s established approval history does not remove product-specific development, quality, regulatory or commercial work. Request a protocol and sample-size rationale, manufacturing scope, stability plan, jurisdiction and vendor quotes before attaching dollars or dates. Stage the estimate around explicit deliverables and contingency assumptions. The audit supplies no selected sponsor program or costed execution plan, so this page should show the required budget inputs rather than a fictional financing target.
Sources: LABEL; GENERIC; RECALL
analyst-16 — What patents and exclusivity need checking?
Established. Teva’s 2010 announcement establishes a historical generic approval milestone for Cozaar and Hyzaar equivalents. It does not establish freedom to operate for a new formulation, process, combination or indication today. Review current Orange Book listings for the precise product and application, then conduct a jurisdiction-specific patent and claim search with qualified counsel. Distinguish regulatory exclusivity, listed patents and broader process or formulation rights. Generic availability is useful commercial context, but it is not a legal opinion or proof that every proposed development path is unrestricted.
analyst-18 — What would support reimbursement and pricing?
Established. For a mature generic, current exact-product acquisition costs, payer formularies, reimbursement rules and supply reliability matter more than a historical branded list price. The prior site snapshot expired on October 16 and should not support a current numerical claim. A new product would need evidence of incremental benefit or practical value against available alternatives, together with a defined payer population and price assumption. Record strength, quantity, manufacturer, date and included fees for any future quote. Utilization estimates cannot substitute for net-price or reimbursement evidence.
analyst-19 — What does recall history imply for manufacture?
Established. FDA’s 2018–2019 ARB updates include affected losartan products and lots with nitrosamine impurities. This makes process understanding, impurity testing, supplier qualification, change control and lot traceability relevant diligence subjects. It does not show that every current product is unsafe or that every current lot has been independently verified by this review. Ask for current manufacturer-specific quality evidence and recall checks, then assess continuity of supply and remediation history. Historical recall volume alone does not determine manufacturing cost, present compliance or the safety of an unidentified bottle.
Sources: RECALL
General
Losartan blocks AT1, the receptor that receives a vessel-tightening message from angiotensin II. Its active metabolite, EXP3174 (E-3174), helps block the same signal in blood vessels, adrenal glands and kidneys. Blood pressure falls over several weeks. The LIFE trial compared two treatment plans in 9,193 people with high pressure and a thickened heart; strokes were less frequent with the losartan plan. Small studies also found lower blood urate, a separate effect linked to kidney transport. A 2026 structure shows the drug bound to an engineered receptor, building on earlier structural research.
Limits: Educational draft; individual treatment and final clinical review require a qualified professional.
Questions for this perspective
1 drafted questions in this packet. Targeted additions or replacements for the current guide.
other-10 — How was losartan discovered?
Established. Losartan came from a search for small molecules that could block the angiotensin II receptor. Papers from 1990 and 1991 described changes to ring and acid groups that improved receptor binding. The 1991 paper included DuP 753, later named losartan. It was already in development by then. Researchers also found an active product of losartan metabolism, EXP3174 (E-3174). The US label lists 1995 as the first approval year. Later trials tested stroke and kidney outcomes in selected patients. Newer studies show losartan bound to an engineered receptor, adding a molecular view to this earlier work.
Sources: SAR; METAB; LABEL; STRUCT
[VERIFY: final merged role routing, exact-answer precedence, retained answers, source rendering and clinical/reader comprehension checks. Analyst historical/current-market claims require manual verification.]
Trials, pharmacokinetics and questions to ask
Pharmacokinetics at a glance
All twelve rows: LABEL §12.3; onset §14.1.
| Parameter | Label finding | Interpretation |
|---|---|---|
| Absorption / bioavailability | About 33% oral systemic bioavailability after first-pass metabolism. Food lowers peak concentration and causes a minor, approximately 10% AUC reduction. | Do not confuse absorption fraction with systemic availability. |
| Time to peak | Parent about 1 hour; EXP3174 (E-3174) about 3–4 hours. | Plasma peak is not time to maximum blood-pressure benefit. |
| Half-life | Parent about 2 hours; active metabolite 6–9 hours. | The parent half-life alone does not determine the dosing interval. |
| Protein binding | Free fractions 1.3% parent and 0.2% metabolite, equivalent to 98.7% and 99.8% bound. | Interpret in-vitro concentrations using unbound exposure. |
| Distribution | Volumes 34 L parent and 12 L active metabolite. | These are apparent distribution parameters, not organ concentrations. |
| Metabolic pathway | Oxidation of the 5-hydroxymethyl group forms active carboxylic acid; in-vitro CYP2C9/CYP3A4, primarily CYP2C9 in human interaction data. | Do not imply equal clinical contributions of both enzymes. |
| Active metabolite | About 14% of the oral dose converts; metabolite AUC about 4 times parent; potency 10–40 times by weight in pharmacology experiments. | Exposure ratio is not a patient dose-conversion ratio. |
| Elimination | Oral radiolabel: about 35% in urine and 60% in feces. About 4% of oral dose appears in urine unchanged and 6% as active metabolite. | Radiolabel recovery includes metabolites; it is not all unchanged parent. |
| Clearance / accumulation | Plasma clearance about 600 mL/min parent, 50 mL/min metabolite; renal clearance 75/25 mL/min. Neither accumulates with once-daily dosing in label studies. | Context is studied regimens and populations, not every circumstance. |
| Renal impairment / dialysis | Mild/moderate impairment raises parent/metabolite concentrations and AUC 50–90%; neither is removed by hemodialysis. | Initial dose is not automatically adjusted for renal impairment alone; volume and safety assessment matter. |
| Hepatic impairment | Mild/moderate alcoholic cirrhosis: parent exposure about 5 times and active metabolite about 1.7 times healthy controls; label start 25 mg. Severe impairment unstudied. | This describes a labeled starting-dose context, not personal prescribing advice. |
| Interactions / clinical onset | Fluconazole: metabolite AUC↓40%, parent↑70%; rifampin: parent↓30%, metabolite↓40%. Substantial BP response within 1 week, maximum 3–6 weeks. | No universal compensatory dose change follows from these PK findings. |
Landmark trials: keep the estimands distinct
Absolute differences below use crude observed participant counts: comparator proportion minus losartan proportion. Reciprocal values and upward-rounded integers are descriptive over each trial's observed follow-up, not adjusted fixed-time Kaplan–Meier NNTs. They do not transfer to another baseline risk or duration.
| Trial and population | Regimens / follow-up | Results and interpretation |
|---|---|---|
| LIFE: 9,193 adults aged 55–80, hypertension plus ECG LVH | Losartan-based n=4,605 versus atenolol-based n=4,588; common add-on HCTZ; mean 4.8 years | Primary CV death/nonfatal MI/nonfatal stroke: 508/4,605 (11.03%) versus 588/4,588 (12.82%); crude ARR 1.785 percentage points, reciprocal 56.04, upward integer NNT 57. Adjusted relative risk 0.87 (95% CI 0.77–0.98). |
| LIFE secondary all-stroke endpoint | Same population and follow-up | Fatal/nonfatal stroke: 232/4,605 (5.04%) versus 309/4,588 (6.73%); crude ARR 1.697 points, reciprocal 58.93, upward integer NNT 59. Adjusted RR 0.75 (0.63–0.89). Not the first-event nonfatal-stroke component, whose counts are 209/286. |
| RENAAL: 1,513 participants with type 2 diabetes and nephropathy | Losartan n=751 versus placebo n=762, added to other permitted BP therapy; mean 3.4 years | Doubling of creatinine, ESRD or death: 327/751 (43.54%) versus 359/762 (47.11%); crude ARR 3.571 points, reciprocal 28.004, approximately 28 or strict upward integer NNT 29. Time-to-event risk reduction 16.1% (95% CI 2.3–27.9) in label analysis. |
| RENAAL components | Same participants and follow-up | ESRD 147/751 versus 194/762; crude ARR 5.885 points, upward integer NNT 17. Creatinine doubling 162/751 versus 198/762. Death 158/751 versus 155/762: no demonstrated reduction. Components overlap and must not be added. |
| ELITE: 722 adults ≥65 with NYHA II–IV HFrEF, EF≤40%, ACE-inhibitor naive | Losartan n=352, target 50 mg once daily; captopril n=370, target 50 mg three times daily; 48 weeks | Primary persistent creatinine rise ≥0.3 mg/dL: 10.5% in both groups, no observed absolute difference, no finite beneficial NNT. Exploratory mortality 4.8% versus 8.7% was unexpected and not a confirmatory survival result. Withdrawal for adverse effects 12.2% versus 20.8%. |
| ELITE II: 3,152 adults ≥60 with NYHA II–IV HFrEF, EF≤40% | Losartan n=1,578 versus captopril n=1,574, same target doses as ELITE; median 555 days | Average annual mortality 11.7% versus 10.4%; HR 1.13 (95.7% CI 0.95–1.35), p=0.16. No superiority demonstrated. These are annual rates, not cumulative risks, so no count-based ARR/NNT is calculated. Adverse-effect discontinuation excluding deaths 9.7% versus 14.7%; cough withdrawal 0.3% versus 2.7%. |
LIFE; RENAAL; CANADA; ELITE; ELITE2; LABEL
LIFE's final mean BP was 144.1/81.3 versus 145.4/80.9 mmHg: similar, not equal. Cardiovascular mortality and MI separately were not significantly reduced. Label §1.2 says, “There is evidence that this benefit does not apply to Black patients.” In the subgroup, primary events were 46/270 (17%) versus 29/263 (11%); the cause and chance contribution remain uncertain. This limits the supported stroke-risk-reduction claim, not every use of losartan and not eligibility based on an inferred biological rule.
Patient natural frequencies — LIFE (two sentences): Over about five years, roughly 5 in 100 people on the losartan plan had a stroke, compared with about 7 in 100 on the atenolol plan. These people had high blood pressure and a thickened heart, and the label notes a limit to the stroke benefit in Black participants.
Patient natural frequencies — RENAAL (two sentences): Over about three and a half years, roughly 44 in 100 people on losartan had a major kidney problem or died, compared with 47 in 100 on placebo-based care. The study involved people with type 2 diabetes and kidney disease; it did not show fewer deaths on their own.
ELITE explanation (two sentences): In the first study, about 11 in 100 people in each group had the blood-test change that was the main outcome. The later, larger study did not show that losartan helped people live longer than captopril; its annual death rates cannot be read as counts out of 100 over the whole study.
Guideline placement
| Guideline | Specific recommendation and boundary |
|---|---|
| 2025 AHA/ACC hypertension, §5.2.3 | ARBs, ACE inhibitors, thiazide-type diuretics and long-acting dihydropyridine calcium-channel blockers are first-line classes. This is not proof that losartan is best for every patient. Exact class/level wording beyond this checked recommendation remains a release check. |
| 2024 ESC elevated BP/hypertension | The same four major classes form first-line options; this source concerns hypertension, not a newly inferred HFrEF hierarchy. |
| 2022 AHA/ACC/HFSA HF | ARNI for NYHA II–III HFrEF: Class 1A. ACE inhibitor when ARNI not feasible: Class 1A in chronic symptomatic HFrEF. ARB for previous/current symptoms of chronic HFrEF when ACE intolerance is due to cough or angioedema and ARNI is not feasible: Class 1A. Do not attribute this entire placement to ELITE II. |
| KDIGO 2024 §3.6 | ACEi/ARB for G1–G4 CKD with A3 albuminuria without diabetes:1B; A2 without diabetes:2C; A2/A3 with diabetes:1B. Avoid ACEi/ARB/direct-renin-inhibitor combinations:1B. |
| KDIGO practice points3.6.1–3.6.5 | Highest approved tolerated dose; check BP/creatinine/potassium within 2–4 weeks based on GFR and potassium. Manage hyperkalemia where possible rather than reflexively stopping. Continue unless creatinine rises >30% within 4 weeks of initiation/increase; symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or selected end-stage circumstances require reassessment. |
Creatinine thresholds are decision aids, not automatic reassurance. Evaluate illness, perfusion, NSAIDs, potassium and the broader clinical course. No patient should derive an individual dose or hold instruction from this table.
Urate: a second mechanism with bounded evidence
Established: URAT1, encoded by SLC22A12, handles renal urate reabsorption. Losartan inhibits this transport in experimental systems, and small clinical studies show increased urate clearance and lower serum urate. Würzner's 13-person crossover comparison found losartan reduced serum urate from 538±26 to 491±20µmol/L, while irbesartan did not; doubling the daily administration did not add a clear reduction in that study. Hamada compared losartan and candesartan in 32 hypertensive patients and included nine people with idiopathic hypouricemia; URAT1 function helped explain the response. These are not large gout-flare or renal-outcome trials.
Limits: Iwanaga's oocyte study found URAT1 inhibition with telmisartan as well, and effects varied with experimental conditions. Do not claim absolute biochemical exclusivity across every ARB, assume active metabolite and parent behave identically, or replace gout treatment with losartan on this basis.
Mechanism-based harms and checks
| Mechanism | Risk / practical question |
|---|---|
| Less aldosterone | Potassium can rise; reconcile supplements, potassium salt substitutes and potassium-sparing drugs. |
| Less angiotensin-dependent filtration pressure | Creatinine can rise or AKI occur, especially with volume loss, renal artery disease, CKD or severe HF; evaluate cause and trend. |
| Reduced vasoconstriction | Symptomatic hypotension, especially in salt/volume depletion. |
| Fetal RAS blockade | Boxed fetal injury/death warning; the label calls for discontinuation as soon as pregnancy is detected and prompt clinical action. |
| Hypersensitivity | Contraindicated with hypersensitivity to any component; swelling affecting breathing requires urgent care. |
| Dual RAS blockade | Aliskiren with losartan is contraindicated in diabetes; combinations generally increase renal, potassium and hypotension risks. |
| No direct ACE inhibition | Less characteristic ACE-related cough, not zero cough or zero angioedema. |
The Cozaar label describes VA NEPHRON-D: 1,448 participants with diabetic albuminuric CKD received background losartan with lisinopril or placebo; no additional primary benefit and more AKI/hyperkalemia occurred. Its historical dual-blockade regimen is not a recommendation. Tablet potassium content is 2.12/4.24/8.48 mg for 25/50/100 mg strengths; hormonal renal effects explain the main hyperkalemia risk.
Class comparison: chemistry and evidence are different axes
| Agent | Active form / half-life | What can be compared responsibly |
|---|---|---|
| Losartan | Active parent plus EXP3174 (E-3174); about 2 h/6–9 h | LIFE/RENAAL are population-specific; small human urate comparisons support an additional pharmacodynamic effect. |
| Valsartan | Active parent; about 6 h | Label includes hypertension, HF and post-MI evidence contexts. Its trial evidence is not a head-to-head efficacy ranking against every ARB. |
| Olmesartan medoxomil | Ester prodrug→olmesartan; about 13 h | Hypertension label; ROADMAP's microalbuminuria endpoint must not be recast as proven kidney-failure or survival benefit. |
| Telmisartan | Active parent; about 24 h | ONTARGET provides a different high-risk population/comparator context. Experimental URAT1 inhibition does not establish the same clinical urate effect as losartan. |
| Candesartan cilexetil | Ester prodrug→candesartan; about 9 h | CHARM HF programs support distinct outcome claims; prodrug status and half-life do not establish superiority. |
| Lisinopril | Active ACE inhibitor; effective accumulation half-life about 12 h | Acts upstream and affects bradykinin degradation; review its own HF/post-MI/HTN evidence and cough/angioedema risks. |
| Sacubitril/valsartan | Neprilysin inhibitor plus ARB | Separate combination and HFrEF guideline role; not an interchangeable single-agent ARB comparison. |
LABEL; COMPARATORS; URAT; HF; DUAL; Zestril §12.3, retained and checked in the lisinopril packet. No matched-dose potency ladder is supplied: assay affinity, pressure reduction and outcome benefit are not interchangeable measurements.
How it was discovered
Losartan grew from medicinal-chemistry efforts to block angiotensin II with an orally useful, nonpeptide molecule. Duncia and colleagues reported in 1990 that adding an aromatic ring and placing acidic and lipophilic groups appropriately improved antagonist activity. Carini’s 1991 work developed the biphenyl imidazole series and described the series containing tetrazole-bearing DuP 753, later called losartan. The parent was active, and Wong’s 1990 experiments characterized its more potent carboxylic acid metabolite, EXP3174 (E-3174). The US label records initial approval in 1995. RENAAL and LIFE subsequently tested kidney and cardiovascular outcomes in defined populations, moving beyond blood-pressure measurements alone. Teva announced generic approval in 2010. Structural research later supplied molecular views of receptor antagonism, including a losartan-bound complex reported before the 2026 engineered 9ZXC structure. This history separates chemical discovery, regulatory approval, clinical outcomes and structural explanation; none is a substitute for the others.
Sources: SAR; METAB; LABEL; RENAAL; LIFE; GENERIC; STRUCT; PRIORSTRUCT
[VERIFY: exact early Takeda/DuPont program dates and original historical accounts; initial approval and generic-entry dates before publication.]
Questions to ask your pharmacist
- What is the goal of my losartan treatment, and how will we track it?
- Does another bottle, such as Hyzaar, also contain losartan?
- When are my next blood-pressure, potassium and kidney checks?
- Could my pain pills, supplements or salt substitute affect it?
- What is our plan if vomiting or diarrhea makes it hard to drink?
- What do I need to know about pregnancy plans or pregnancy while taking it?
- If a liquid is prescribed, can you show me its measure, shaking and storage steps?
- Can you check my exact refill product, supply, recall status and current cost?
Common misconceptions
- “An ARB is a weaker ACE inhibitor.” It blocks a receptor instead of ACE. Relative benefit depends on indication, regimen and evidence, not a single strength label.
- “The potassium salt is natural, so salt substitutes are safe.” Blood potassium can rise through renal hormonal effects; potassium-containing substitutes need review.
- “Higher renin means the drug stopped working.” Feedback can raise renin/angiotensin during effective AT1 blockade.
- “No cough means no breathing-related risk.” Cough can occur and angioedema remains a serious concern.
- “Urate lowering means it treats gout.” Small biochemical studies do not establish replacement of gout therapy or prevention of attacks.
- “A recalled lot means all current losartan is unsafe.” Recall conclusions are product/lot/time specific.
LABEL; URAT; URATECLIN; RECALL
[VERIFY: final clinical review, all comparator labels and trial-source alignment, exact guideline tables where full text was blocked, historical/current market and price checks, textbook chapter references and source/visual rights.]
Reference pack
Source codes in the text resolve to the references below. Retrieval and clinical-review status are distinct.
25 grouped entries. Retrieval scope is explicit; source verification is not clinical review.
LABEL
Cozaar, Organon, US prescribing information, §§1–2,4–8,11–12,14,17
Retained SPL v9, effective 2026-01-20, revised 6/2025; relevant full clinical sections read. Dates describe the source, not clinical review.
LIFE
Dahlöf et al. LIFE, 2002; PMID11937178; DOI10.1016/S0140-6736(02)08089-3
Primary abstract read. Arm denominators and endpoint types checked against Canadian Cozaar monograph, Table13, page33.
RENAAL
Brenner et al. RENAAL, 2001; PMID11565518; DOI10.1056/NEJMoa011161
Primary abstract plus US label§14.3. Exact counts independently checked in Canadian monograph page29.
CANADA
Health Canada, Cozaar product monograph, tables11–13
46-page PDF retained; pages29 and33 visually inspected. Used to corroborate trial denominators, not replace US indication scope.
ELITE
Pitt et al. ELITE, 1997; PMID9074572; DOI10.1016/S0140-6736(97)01187-2
Primary abstract read; renal tolerability primary endpoint, exploratory survival finding.
ELITE2
Pitt et al. ELITE II, 2000; PMID10821361; DOI10.1016/S0140-6736(00)02213-3
Primary abstract read; annual mortality rates must not be recast as cumulative risks. Reported mortality confidence level is95.7%.
METAB
Wong et al. EXP3174 pharmacology, 1990; PMID2213556
Primary abstract retained; preclinical functional antagonism, not human superiority proof.
SAR
Duncia et al.1990 PMID2329553; Carini et al.1991 PMID1875348
Both primary abstracts retained; Carini, DOI10.1021/jm00112a031. Duncia DOI10.1021/jm00167a007. Do not infer exact Takeda/DuPont calendar milestones from abstract alone.
STRUCT
Skiba et al.2026 PMID42550893; DOI10.1073/pnas.2602538123; PDB9ZXC
Entry and coordinates retained, 3.4Å cryo-EM. Full paper read for matched losartan antagonist structure and construct limits. Paper gives3.3Å for this map; retain entry-specific3.4Å.
PRIORSTRUCT
Identified and discussed in2026 full paper as prior losartan-bound AT118-L structure; full2024 XML retrieval failed. 2026 is not the first losartan-bound receptor structure.
PLC
Ushio-Fukai et al.1998; PMID9677408; DOI10.1074/jbc.273.31.19772
Primary abstract read: rat vascular smooth-muscle PLC signaling has early and later components, not one exclusive linear route.
URAT
Enomoto2002 PMID12024214; Iwanaga2007 PMID17043154; Hamada2008 PMID18670416
URAT1 identification DOI10.1038/nature742; ARB transport study DOI10.1124/jpet.106.112755; human study DOI10.1038/ajh.2008.245. Abstracts read. In-vitro telmisartan inhibition prevents a universal no-other-ARB claim.
URATECLIN
Würzner et al.2001; PMID11593107; DOI10.1097/00004872-200110000-00021
13 completed crossover participants with hypertension, hyperuricemia and gout; biochemical urate result, not gout-flare prevention trial.
HF
2022 AHA/ACC/HFSA heart-failure guideline; PMID35363499
Official slides pages70–72 read through browser; local download403. ARNI/ACEi/ARB recommendation conditions verified.
USHTN
2025 AHA/ACC hypertension guideline; PMID40811516; DOI10.1016/j.jacc.2025.05.007
Primary indexed section5.2.3 and official AHA summary checked. Full local article403; do not assign an unverified exact recommendation grade.
KDIGO
KDIGO2024 CKD guideline §3.6; PMID38490803
Full PDF retained; recommendations3.6.1–3.6.4 and practice points3.6.1–3.6.5 checked.
ESC
McEvoy et al.2024 ESC hypertension guideline; PMID39210715; DOI10.1093/eurheartj/ehae178
Primary indexed first-line class recommendation checked; complete publisher text blocked. This is a hypertension guideline, not an HF guideline.
COMPARATORS
Diovan, Benicar, Micardis and Atacand US prescribing information
Retained full labels; PK/prodrug sections checked. Benicar, Micardis, Atacand. No matched-dose potency ranking.
PATIENT
Patient guidance retained and read; NHS retained. Product-specific US label controls medical scope.
VOLUME
ClinCalc DrugStats, losartan2024 estimates
Retained page: rank7;59,030,486 prescriptions;15,388,926 patients. Secondary MEPS-derived survey estimates, not revenue or a national dispensing census.
GENERIC
Teva, April7,2010, Final Approval of Generic Hyzaar and Cozaar
Manufacturer announcement retained; current Orange Book status requires a separate check.
RECALL
FDA ARB recall updates and press announcements
Official browser page read; local fetch blocked. Losartan2018NDEA and2019NMBA affected products/lots. Not a finding about every current lot or every ARB.
OLDERSTRUCT
Zhang et al.2015; PMID25913193; DOI10.1016/j.cell.2015.04.011
Primary abstract read:2.9Å AT1R–ZD7155 crystal structure. Do not label this losartan-bound experimental structure.
DUAL
ONTARGET,2008; PMID18378520; plus VA NEPHRON-D as summarized in Cozaar§7.4
ONTARGET abstract retained. Label directly describes1448 participants on losartan with lisinopril/placebo, no added primary benefit and increased AKI/hyperkalemia.
TEXTBOOK
Katzung16e and Goodman & Gilman14e, renin–angiotensin and antihypertensive chapters
[VERIFY: exact chapter authors/numbers/pages and licensed text before making chapter-specific claims.] Portal is not verification.
[VERIFY: founder manual confirmation of approval/label revision/history/generic-entry dates, current market estimates, recalls, product availability and source licensing before publication.]
Editorial review notes
Marked verification items remain unresolved. Source checks and reading-grade checks do not constitute clinical approval.
Claim-by-claim accuracy check
Before text: full losartan dossier and audit. This is an editorial repair, not a live-site change.
| Claim or gap | Finding / change | Evidence |
|---|---|---|
| Dossier: blocks a receptor rather than ACE | Keep; name AT1, vascular/adrenal/kidney pathway and active EXP3174 (E-3174). | LABEL |
| Ten introductions only24–30words | Expand to60–120 with distinct decisions and measured effect, preserving mechanism. | LABEL; LIFE; RENAAL |
| Audit: CYP2C9/3A4 conversion | In-vitro evidence involves both; human interaction data indicate primarily CYP2C9, not3A4.14% conversion is fraction of oral dose. | LABEL |
| Active metabolite10–40times stronger | Specify potency by weight in label experiments, not clinical superiority or a dose-conversion factor. | LABEL; METAB |
| Audit: no cough / expect no heart-rate change | Replace zero-risk wording: no direct ACE/bradykinin inhibition; cough still occurs. Trial mean heart rate was essentially unchanged, not a guarantee. | LABEL; ELITE2 |
| LIFE equal blood pressure | Similar, not equal: final144.1/81.3 vs145.4/80.9mmHg. Primary composite differs from secondary all-stroke outcome. | LABEL; LIFE; CANADA |
| LIFE Black-patient limitation | Retain exact label scope: stroke-risk reduction in hypertension plus LVH.46/270 vs29/263; uncertain cause. Not a contraindication or a claim about all uses. | LABEL |
| RENAAL43.5vs47.1;NNTabout28 | Give751/762denominators and mean3.4yr. Rounded risks yieldabout28; exact count reciprocal28.004 rounds upward29. State method, do not confuse adjusted16%relative reduction with crude relative risk. | RENAAL; CANADA; LABEL |
| ELITE II failure proves ARBs inferior | No mortality superiority demonstrated; not proof of equivalence or inferiority. Annual rates cannot yield cumulative ARR/NNT. Current guideline conditions separately sourced. | ELITE; ELITE2; HF |
| Audit: accept creatinine rise about30% | KDIGO continuation practice point is conditional; assess volume, potassium, interactions and clinical deterioration. More than30% within4wk requires evaluation. | KDIGO; LABEL |
| Uricosuric effect unique to losartan / all other ARBs do not lower urate | Human comparison supports losartan versus irbesartan/candesartan in selected small studies. Telmisartan also inhibited URAT1 in vitro; no universal class exclusivity or gout treatment claim. | URAT; URATECLIN |
| Audit: first receptor picture only2026 | 2026 paper explicitly cites prior2024 losartan-bound structure.9ZXC is engineered AT118-R complex;2015 structure has ZD7155. | STRUCT; PRIORSTRUCT; OLDERSTRUCT |
| 9ZXC3.40Å | Keep RCSB entry resolution and nanobody/construct limits. Paper reports3.3Å; discrepancy disclosed. Coordinate proximity is not proof of a hydrogen bond or native affinity. | STRUCT |
| Audit label more than1000-fold affinity | Current Cozaar text says about1000-fold for AT1 over AT2. Retain current source wording. | LABEL |
| Audit current supply is tested | Historical recall evidence does not verify every current lot. Refer exact manufacturer/lot to FDA and pharmacist. | RECALL |
| History refusal | Replace with primary SAR records, metabolite discovery and label1995milestone; Teva2010announcement. Exact early-program dates remain flagged. | SAR; METAB; LABEL; GENERIC |
| Patientq5 andq18 duplicated | Separate response tracking from laboratory safety; retain source-specific indications. | LABEL; KDIGO |
| nurse-07/caregiver-11 raw objects | Use actual question bank: infusion compatibility and inhaler/device. Replace objects with route-specific sentences; liquid measuring device remains relevant. | LABEL; PATIENT |
| Expiry2026-10-16 | Remove dated numeric quote from implementation draft; exact pack/date check needed before any replacement. | VOLUME |
Decisions made for the founder
Correct the audit's absolute cough, class-unique URAT1, equal-BP, first-2026-structure and unconditional creatinine claims. These corrections are supported by current primary sources; no safety-relevant missed error in live content has been established. Use Cozaar consistently while retaining formulation-specific exceptions. Full trial panels carry numbers that cannot fit safely in a120-word introduction. Keep the selector and useful existing Gen1 answers.
[VERIFY: final merged safety/routing, label dates, historical/regulatory milestones, comparator source currency, current recalls/prices/IP, clinical and native-language review.]
Plain-language checks
Method: textstat Flesch–Kincaid grade on the exact saved paragraph/answer bodies. Source links, headings and notes are excluded. Original mechanism paragraphs come from the dossier’s per-perspective mechanism data; after paragraphs come from the final saved 03-perspectives.md. FAQ text comes from the dossier and final 04-faq-by-perspective.md. Automated grades estimate sentence difficulty; they do not establish comprehension or clinical accuracy. Patient/Caregiver grades below 6 are acceptable when the wording is clear and preserves meaning. General target is 8–10.
Introduction readings
| Role | Before words | Before FK | After words | After FK |
|---|---|---|---|---|
| Patient | 24 | 11.71 | 97 | 5.07 |
| Caregiver | 27 | 13.28 | 92 | 5.95 |
| Pharmacist | 26 | 15.80 | 90 | 14.65 |
| Clinician | 29 | 16.51 | 101 | 12.50 |
| Nurse | 26 | 10.81 | 87 | 11.91 |
| Student | 24 | 13.67 | 87 | 15.43 |
| Scientist | 30 | 16.22 | 90 | 15.30 |
| Chemist | 28 | 15.16 | 88 | 14.67 |
| Investor / Diligence Analyst | 26 | 16.71 | 107 | 10.92 |
| General | 27 | 7.16 | 91 | 8.87 |
Patient
Before (actual dossier): Losartan blocks a receptor that receives a blood-vessel-tightening signal called angiotensin II. Blood vessels relax and salt-and-water hormone signals change, helping lower blood pressure.
After (saved perspective draft): Losartan blocks AT1, a switch that a hormone uses to squeeze blood vessels. Your body also makes an active form, EXP3174 (E-3174), which helps block it. Vessels relax, and kidney salt signals change. Blood pressure starts to fall within a week; the full effect can take 3–6 weeks. Blood tests check kidney function and potassium, a salt in the blood. The boxed warning says it can harm or kill an unborn baby. The label also rules out use after allergy to its contents, or with aliskiren in people with diabetes. Ask your care team about these risks.
FK before 11.71; after 5.07.
Caregiver
Before (actual dossier): Losartan stops angiotensin II from delivering much of its vessel-tightening message. The effect is assessed with blood-pressure readings and follow-up, not whether the person immediately feels different.
After (saved perspective draft): Losartan and its active form, EXP3174 (E-3174), block AT1 switches in blood vessels, kidneys and the adrenal glands. This lowers blood pressure over weeks. Keep a record of readings, falls, poor intake and new medicines. Ask the pharmacist about pain pills such as ibuprofen and salt substitutes that contain potassium. Cozaar contains losartan; Hyzaar adds a water pill. Check the full name to avoid mix-ups. The boxed warning says losartan can harm or kill an unborn baby. Ask the care team for an illness plan if the person cannot keep fluids down.
FK before 13.28; after 5.95.
Pharmacist
Before (actual dossier): Losartan and its active metabolite block AT1 receptors, reducing angiotensin-II-driven vasoconstriction and aldosterone release. Unlike ACE inhibitors, they do not directly inhibit ACE or bradykinin degradation.
After (saved perspective draft): Losartan and EXP3174 (E-3174) block vascular, adrenal and renal AT1 signaling to lower pressure. About 14% of an oral dose forms this active metabolite,10–40 times more potent by weight, with 6–9-hour half-life. Human interaction data primarily implicate CYP2C9: fluconazole lowers metabolite exposure and rifampin lowers both exposures. Reconcile potassium, NSAIDs, lithium and dual RAS blockade; URAT1-linked uricosuria is a selection consideration, not gout treatment. The boxed warning concerns fetal toxicity; hypersensitivity and aliskiren coadministration in diabetes are contraindications. Check volume depletion, hepatic impairment and formulation-specific suspension storage against the label.
FK before 15.80; after 14.65.
Clinician
Before (actual dossier): AT1 antagonism by losartan and its active metabolite reduces vasoconstrictor and aldosterone responses to angiotensin II. The pathway remains blocked despite feedback increases in renin and circulating angiotensin II.
After (saved perspective draft): Losartan and EXP3174 (E-3174) antagonize vascular, adrenal and renal AT1 signaling. In RENAAL, the renal/death composite occurred in 327/751 versus 359/762 over mean 3.4 years; mortality alone was not reduced. LIFE primary events were 508/4605 versus 588/4588 over 4.8 years; stroke counts 232 versus 309 have the label’s Black-patient limitation. ELITE II (1578 versus 1574) did not establish mortality superiority over captopril;2022 HF guidance conditions ARB use on ACE intolerance and ARNI infeasibility. KDIGO 2024 guides albuminuric CKD treatment and monitoring. URAT1-related urate lowering informs comorbidity discussion, not gout substitution. Boxed fetal toxicity, hypersensitivity and aliskiren with diabetes require explicit screening.
FK before 16.51; after 12.50.
Nurse
Before (actual dossier): Losartan blocks angiotensin-II signals that tighten vessels and promote aldosterone release. Blood pressure, kidney function and potassium help assess consequences of this pathway, not just symptoms.
After (saved perspective draft): Losartan and EXP3174 (E-3174) block AT1 responses in vessels, adrenal glands and kidneys. Lower aldosterone can raise potassium; altered kidney filtration pressure can raise creatinine. Pressure reduction starts within a week and develops over 3–6 weeks. Check ordered blood-pressure parameters, fluid status, kidney results and potassium, particularly after illness or treatment changes. The boxed warning identifies fetal injury or death; flag pregnancy promptly. Hypersensitivity and aliskiren use in diabetes are contraindications. Teach-back should confirm why blood tests matter and whom to call if vomiting prevents fluid intake.
FK before 10.81; after 11.91.
Student
Before (actual dossier): Angiotensin II activates AT1 receptors to promote vasoconstriction and aldosterone release. Losartan blocks the receptor, rather than the ACE enzyme that produces angiotensin II.
After (saved perspective draft): Losartan and EXP3174 (E-3174) antagonize AT1 receptors in vascular smooth muscle, adrenal tissue and the kidney. Blocking Gq/11–PLC–IP3/Ca2+ signaling reduces contraction; less aldosterone changes sodium and potassium handling, while efferent arteriolar effects alter filtration pressure. Blood pressure falls over weeks. Renin and angiotensin II rise through feedback even during effective blockade; AT2 remains available. Parent losartan is active, whereas the metabolite has greater functional potency and a 6–9-hour half-life. Reversible insurmountable antagonism in an experiment does not mean covalent binding or prove clinical superiority over another ARB.
FK before 13.67; after 15.43.
Scientist
Before (actual dossier): Losartan and its active metabolite antagonize AT1 signaling without inhibiting ACE. Separate receptor antagonism from feedback increases in renin; rising upstream hormone concentrations do not alone establish loss of blockade.
After (saved perspective draft): Losartan and EXP3174 (E-3174) antagonize AT1 signaling in vascular, adrenal and renal tissues, lowering blood pressure. Established evidence includes label pharmacology, LIFE/RENAAL outcomes and the engineered losartan-bound 9ZXC structure in Skiba 2026. URAT1 inhibition and small human studies support a separate uricosuric action. Probable contribution of persistent metabolite activity to duration is distinct from proving that one functional antagonism assay explains the clinical effect. Uncertain clinical contribution of unopposed AT2 signaling remains a testable question. The 3.4Å entry uses a nanobody-stabilized construct, not an unmodified receptor in a living kidney.
FK before 16.22; after 15.30.
Chemist
Before (actual dossier): Losartan is an AT1 antagonist with a more potent active metabolite. Binding studies distinguish competitive parent antagonism from the metabolite's different functional behavior; neither acts by ACE inhibition.
After (saved perspective draft): Losartan potassium combines an acidic biphenyl tetrazole with a 2-butyl-4-chloro-imidazole bearing a 5-hydroxymethyl group. Oxidation yields the carboxylic acid EXP3174 (E-3174), alongside an already active parent. Both antagonize AT1 in vessels, adrenal glands and kidneys, lowering pressure. Duncia/Carini SAR supports the ortho acidic group and lipophilic substituents; current human interaction data primarily implicate CYP2C9 in metabolite formation. Skiba 2026 and PDB 9ZXC place ligand LSN in an engineered receptor complex at 3.4Å. The potassium counterion describes the salt; elevated serum potassium follows chiefly from altered renal hormonal physiology.
FK before 15.16; after 14.67.
Investor / Diligence Analyst
Before (actual dossier): Losartan interrupts angiotensin-II signaling at AT1 receptors, lowering vascular and aldosterone responses. Its known target does not establish interchangeability of formulations or clinical outcomes across populations.
After (saved perspective draft): Losartan and EXP3174 (E-3174) block vascular, adrenal and renal AT1 signaling, supporting a mature blood-pressure franchise. LIFE primary events were 508/4605 versus 588/4588 over 4.8 years; RENAAL 327/751 versus 359/762 over 3.4 years. ELITE II (1578 versus 1574) did not prove mortality superiority. ClinCalc estimates 59.0 million US prescriptions,15.4 million patients and rank 7 in 2024. Teva announced generic approval in 2010. Historical nitrosamine recalls make manufacturer and lot controls material diligence questions. Valsartan, olmesartan and telmisartan compete within the class; sacubitril/valsartan occupies a different HF evidence position. Next checks are current Orange Book entries, payer data and supply records, not an assumed price or exclusivity premium.
FK before 16.71; after 10.92.
General
Before (actual dossier): Losartan blocks the receptor for a signal that narrows blood vessels. Blocking that message helps vessels relax; it does not stop the body from making the signal.
After (saved perspective draft): Losartan blocks AT1, the receptor that receives a vessel-tightening message from angiotensin II. Its active metabolite, EXP3174 (E-3174), helps block the same signal in blood vessels, adrenal glands and kidneys. Blood pressure falls over several weeks. The LIFE trial compared two treatment plans in 9,193 people with high pressure and a thickened heart; strokes were less frequent with the losartan plan. Small studies also found lower blood urate, a separate effect linked to kidney transport. A 2026 structure shows the drug bound to an engineered receptor, building on earlier structural research.
FK before 7.16; after 8.87.
Public FAQ reading-level checks
| FAQ | Before FK | After FK | Check |
|---|---|---|---|
| Patient 05 — How will I know whether it is helping? | 8.67 | 5.76 | Revised answer is below 8; older answer exceeded 8. |
| Patient 18 — Will I need tests or monitoring? | 14.27 | 6.72 | Revised answer is below 8; older answer exceeded 8. |
| Caregiver 11 — device help | Not applicable | 6.78 | Dossier marks this item not applicable; draft correctly explains tablets and the labeled liquid-measuring context. |
| Nurse 07 — dilution, infusion or compatibility | Not applicable | 15.20 | Dossier marks this item not applicable; draft explicitly limits non-applicability to IV checks and retains oral-liquid safeguards. |
| General 10 — How was losartan discovered? | 14.74 | 8.54 | New answer is in the 8–10 target; it adds a sourced discovery chronology beyond the old unresolved placeholder. |
Patient 05 — contextual check
Before (actual dossier): For losartan, look for the treatment goal agreed with the clinician: blood-pressure control and, in diabetic nephropathy, longer-term kidney and urinary-protein trends. You may feel no different despite benefit. Keep a record rather than judging one dose.
After (saved FAQ repair): A series of blood-pressure readings shows more than how you feel after one pill. Losartan starts to lower pressure within a week, with the full effect often reached in 3–6 weeks. Keep the record your care team has asked for and bring it to the next visit. For some people with diabetes and kidney disease, the team also tracks urine protein and kidney health over time. Ask which treatment goal applies to you. One high reading is not a reason to change the dose yourself.
FK before 8.67; after 5.76. The revision uses concrete repeated readings, a realistic 1–6 week response window, an agreed treatment goal, kidney follow-up only for some people with diabetes and kidney disease, and a reminder not to self-adjust after one high reading.
Patient 18 — contextual check
Before (actual dossier default answer): Follow blood pressure, creatinine or estimated filtration, and potassium after initiation and dose changes, then according to clinical risk. In diabetic nephropathy, urinary protein and renal trends help assess the condition over time. Report vomiting, diarrhea, poor intake, NSAID use, or symptomatic low pressure because these can change renal risk.
After (saved FAQ repair): Blood tests check potassium, a salt in the blood, and creatinine, a sign of kidney function. These checks look for risks that you may not feel. For people with chronic kidney disease, KDIGO guidance calls for checks within 2–4 weeks after starting or raising a dose, with timing based on risk. Your care team sets your schedule. Report poor fluid intake, vomiting, diarrhea or new pain pills such as ibuprofen. These can change kidney risk even when the blood-pressure readings look good.
FK before 14.27; after 6.72. The revision explains potassium and creatinine in everyday terms, gives the risk-adjusted 2–4 week check timing for chronic kidney disease, and names fluid loss and NSAIDs as reasons to contact the care team.
Non-applicable role questions
The dossier records caregiver-11 and nurse-07 as not-applicable, not as missing answer text. Their final repairs explain why device/infusion assumptions do not directly apply to losartan while retaining formulation-specific liquid, route, measuring and storage safeguards. These checks assess whether the prompt was handled contextually; they do not add a clinical review.
General FAQ other-10
Before (actual dossier): A detailed, verified account of the original losartan discovery program is not established in this review. The label records initial US approval in 1995, which is a regulatory milestone rather than a discovery date. A discovery narrative should be added only after checking original medicinal-chemistry or development records.
After (saved FAQ repair): Losartan came from a search for small molecules that could block the angiotensin II receptor. Papers from 1990 and 1991 described changes to ring and acid groups that improved receptor binding. The 1991 paper included DuP 753, later named losartan. It was already in development by then. Researchers also found an active product of losartan metabolism, EXP3174 (E-3174). The US label lists 1995 as the first approval year. Later trials tested stroke and kidney outcomes in selected patients. Newer studies show losartan bound to an engineered receptor, adding a molecular view to this earlier work.
FK before 14.74; after 8.54. The revised answer is within the General target range.
Readability decisions
Patient introduction grades: 5.07; Caregiver: 5.95; General: 8.87. Patient/Caregiver drafts are below the 8 ceiling. General is within the required 8–10 range. Pharmacist, Clinician, Nurse, Student, Scientist, Chemist and Investor/Diligence Analyst are technical audiences and are not held to the patient ceiling. No comprehension test or clinical review is claimed.
Fact-preservation check: the patient and caregiver drafts explain AT1/receptor action in familiar terms while retaining the active metabolite, expected onset/full-effect range, blood-test context and pregnancy/contraindication warnings. The specified FAQ repairs distinguish tablet/device and IV prompts from losartan’s oral route while preserving labeled liquid precautions.
Changes and acceptance checks
Changes — 2026-10-18
| Output | Change and reason | Evidence |
|---|---|---|
| 00–02 | Full audit/dossier review, claim-by-claim corrections, one Cozaar reference label, 25 grouped references and retained source receipts. | Cozaar §§1–2,4–8,11–12,14,17; primary studies and guideline records linked in02. |
| 03 | Ten 60–120-word role-specific introductions with AT1, EXP3174 (E-3174), relevant tissues and measured effect; safety warnings and contraindications in required roles. | Label, LIFE, RENAAL, ELITE II, URAT1, structure and guideline sources. |
| 04 | 33 targeted Gen1 answers; five each for Clinician, Pharmacist and Student, seven Analyst replacements, public response/monitoring distinction, raw object repairs and Scientist/Chemist additions. | Exact question-bank IDs checked against raw/js/faq-catalog.js; inline evidence per answer. |
| 05 | Twelve-row PK, four trial programs, actual event counts and calculations, natural frequencies, guideline/urate/harms panels, seven-option comparison, 142-word history, eight pharmacist questions and misconceptions. | Primary abstracts, Cozaar, original Canadian trial tables visually inspected on pages29/33, named guidelines and comparator labels. |
| 06 | Actual before/after public introductions and flagged FAQ repairs with automated grade estimates. | Dossier versus final saved text; readability.json. |
| 07 | Eight retained GIF chapters with concrete alignment changes, proposed ninth outcome chapter, pathway and structure specifications. | 9ZXC coordinates/metadata, Skiba2026, earlier2024 context, label, PLC and trial evidence. |
| 08 | Spanish Patient introduction, response/monitoring answers and safety box, terminology/back-translation and review checklist. | Frozen English draft and Cozaar/KDIGO sources; native professional review pending. |
Decisions made for the founder
- The audit's “no cough,” “equal blood pressure,” “first picture ... only in2026,” universal class-unique URAT1 and “current supply is tested” wording exceeds the supporting evidence. Replace with the narrower documented claims; this is correction of the audit, not a substantiated missed live safety error.
- Use current Cozaar “about1000-fold” AT1/AT2 affinity wording. In-vitro CYP2C9/3A4 participation is distinct from human interaction evidence primarily implicating CYP2C9.
- RENAAL's rounded percentages imply approximately28 treated per observed composite event avoided; exact counts give reciprocal28.004 and strict upward integer29. Show the arithmetic and distinguish crude risk differences from adjusted time-to-event effects. ELITE II annual rates cannot yield a cumulative NNT.
- Do not turn a nonsignificant superiority result into equivalence or inferiority. Do not attribute present HF placement solely to ELITE II. State guideline eligibility conditions.
- The LIFE label limitation concerns the supported stroke-risk-reduction indication in hypertension plus LVH. Preserve that limitation without treating it as a contraindication or extending it to every use or outcome.
- KDIGO's creatinine threshold does not authorize ignoring symptomatic hypotension, hyperkalemia, volume depletion or acute kidney injury.
- Keep the selector, useful existing Gen1 answers and exact-answer precedence. The two status objects receive readable, route-specific answers. Existing strong safety/caregiver answers remain available.
- Numeric prices that expired October16 are withdrawn from the proposed implementation. No current price, IP clearance or supplier quality assurance is invented.
- Apply lower-model subagents to structure/index QA, visual/translation drafting and language measurements; primary-agent review retains difficult evidence interpretation. Drafts remain local; no publication, clinical sign-off or outreach occurred.
Audit acceptance
| Audit §7 item | Draft result and boundary |
|---|---|
| Consistent Cozaar label and metabolite naming | PASS draft alignment; source sections and aliases are explicit. Existing live links still need implementation. |
| Ten introductions60–120words, target/metabolite/tissue/effect | Saved-artifact validator records counts and grades. Each introduction supports a distinct role decision. |
| LIFE, RENAAL, ELITE II numbers in clinical/analyst copy; subgroup wording | PASS in introductions, role FAQs and full trial cards; trial follow-up and annual-rate distinctions retained. Exact label subgroup sentence appears in05. |
| Urate discussion in Pharmacist, Clinician, Scientist and General | PASS; primary human/transport sources included. Audit's universal uniqueness claim corrected. |
| Current named hypertension/HF/KDIGO recommendations | PASS for checked recommendations; exact inaccessible full-table details remain marked for release verification. |
| 9ZXC/Skiba2026 in Scientist and Chemist | PASS; engineered construct and entry/paper resolution discrepancy disclosed, prior2024 structure acknowledged. |
| Analyst volume/rank/generic history/recall/competitors/next checks | PASS as evidence-bounded draft; dated/current business facts remain manual-verification items. |
| Identifiers and new references | PASS expanded bibliography with retrieval scope. New URAT1/human/earlier-structure sources are explicitly listed rather than inventing support from audit citations alone. |
| All shared engagement blocks | PASS drafted:12PK rows, four trial programs, two-sentence natural frequencies,120–180-word history, eight questions; detailed calculations retained. |
| Plain language, targeted FAQ lengths and routing | Saved-file checks and readability.json record final results; final browser routing and comprehension have not been tested. |
Read final-artifact-checks.json for the measured saved-file result. Clinical review, native Spanish review, implemented graphics/audio, live routing, human comprehension and publication are not completed or claimed by draft acceptance.
Open items
[VERIFY: manual confirmation of approval/label revision/generic-entry/history/market dates; original early Takeda/DuPont timeline; current Orange Book/IP, exact-pack prices and manufacturer/lot recall status; exact guideline tables where publisher retrieval failed; current comparator labels and claim alignment; structural residue mapping, atom selections and image rights; textbook chapter details; final clinical, translation, comprehension, mobile/accessibility and routing checks.]
[CITATION NEEDED: original historical records for exact1982/1986 program milestones if retained in final history; measured ionization/affinity datasets and assay conditions before adding numeric pKa or precise potency comparisons absent from this draft.]
[FOUNDER TO SUPPLY: actual qualified clinical reviewer and native Spanish-speaking health-professional reviewer, with signed review records for the final versions.]
All bracketed items feed work/OPEN-ITEMS.md. No intermediate founder response is required. No substantiated safety-relevant live error missed by the audit has been established.
Translation draft — native clinical review pending
Scope: a Spanish patient-facing draft aligned to the exact English Patient introduction in work/losartan/03-perspectives.md and the revised patient FAQ answers patient-05 and patient-18 in work/losartan/04-faq-by-perspective.md. The additional safety box carries the Cozaar label's boxed fetal-toxicity warning and both contraindications. This is translation/editorial work, not clinical validation, a prescribing instruction, or an approved localized site page. Use the same source and review badges as the English draft.
Locked English source: Patient introduction from 03
Losartan blocks AT1, a switch that a hormone uses to squeeze blood vessels. Your body also makes an active form, EXP3174 (E-3174), which helps block it. Vessels relax, and kidney salt signals change. Blood pressure starts to fall within a week; the full effect can take 3–6 weeks. Blood tests check kidney function and potassium, a salt in the blood. The boxed warning says it can harm or kill an unborn baby. The label also rules out use after allergy to its contents, or with aliskiren in people with diabetes. Ask your care team about these risks.
Limits: Educational draft; individual treatment and final clinical review require a qualified professional.
Borrador en español: introducción para pacientes
El losartán bloquea el receptor AT₁, una especie de interruptor que usa una hormona para estrechar los vasos sanguíneos. El cuerpo también produce una forma activa, llamada EXP3174 (E-3174), que ayuda a bloquear ese receptor. Así, los vasos pueden relajarse y cambian las señales que regulan la sal en los riñones. La presión arterial empieza a bajar durante la primera semana; el efecto completo puede tardar de 3 a 6 semanas. Los análisis de sangre revisan la función renal y el potasio. La advertencia destacada indica que el medicamento puede dañar o causar la muerte del bebé en desarrollo. La ficha también prohíbe usarlo si hay alergia a cualquiera de sus componentes o junto con aliskirén si usted tiene diabetes. Consulte estos riesgos con su equipo de salud.
Límites: Borrador educativo; el tratamiento individual y la revisión clínica final requieren un profesional calificado.
Fuentes: ficha de Cozaar, advertencia, §§4, 12 y 17; MedlinePlus, losartán.
Dos respuestas para pacientes, alineadas con 04
¿Cómo sabré si me está ayudando? (patient-05)
Una serie de lecturas de la presión arterial le dice más que cómo se siente después de una sola pastilla. El losartán empieza a bajar la presión durante la primera semana; el efecto completo suele alcanzarse en 3 a 6 semanas. Lleve el registro que le pidió su equipo de salud a la próxima consulta. Si tiene diabetes y enfermedad renal, es posible que también le revisen la proteína en la orina y la salud de los riñones con el tiempo. Pregunte cuál es su meta de tratamiento. Una sola lectura alta no es motivo para cambiar la dosis por su cuenta.
Fuente: ficha de Cozaar, §§12.2 y 14.
¿Necesitaré análisis o seguimiento? (patient-18)
Los análisis de sangre revisan el potasio y la creatinina, que ayuda a evaluar cómo funcionan los riñones. Estos controles buscan problemas que quizá no causen síntomas. Para algunas personas con enfermedad renal crónica, la guía KDIGO recomienda revisar la presión, la creatinina y el potasio entre 2 y 4 semanas después de empezar o aumentar un medicamento de este tipo; el momento depende del riesgo. Su equipo de salud fijará su calendario. Avise si come o bebe muy poco, vomita, tiene diarrea o empieza a tomar analgésicos como ibuprofeno. Todo esto puede cambiar el riesgo para los riñones aunque la presión parezca estar bien.
Fuentes: ficha de Cozaar, §§5 y 12; KDIGO 2024, §3.6.
Recuadro de seguridad que debe viajar con el texto
Embarazo — advertencia destacada. El losartán puede dañar o causar la muerte del bebé en desarrollo. La ficha de Cozaar indica suspender el medicamento tan pronto se detecte un embarazo. Si queda embarazada mientras lo toma, comuníquese de inmediato con el profesional que se lo receta para recibir atención y un plan de tratamiento; no espere a la próxima cita. Si planea un embarazo, consulte antes sobre otras opciones. Esta información no establece un plan individual de cambio de medicamento.
Cuándo no debe usarse según la ficha. Cozaar está contraindicado si usted tiene hipersensibilidad o alergia a cualquiera de sus componentes. También está contraindicado tomarlo junto con aliskirén si tiene diabetes. Lleve una lista de todos sus medicamentos al equipo de salud para que compruebe las combinaciones. La alergia previa a otra medicina no se debe convertir automáticamente en una contraindicación nueva para losartán sin revisar la ficha y el caso.
Fuente: Cozaar, advertencia destacada, §§4, 5.1, 8.1 y 17.
Terminology and back-translation check
| English anchor | Spanish term used | Back-translation / meaning to preserve | QA note |
|---|---|---|---|
| losartan | losartán | same active medicine | Accent and regional generic-name usage to be checked by reviewer. |
| AT1 receptor | receptor AT₁ | angiotensin II type 1 receptor | Keep AT₁ in visual, text and transcript; “interruptor” is a metaphor, not a second molecular target. |
| active metabolite EXP3174 (E-3174) | forma activa, EXP3174 (E-3174) | active form made by the body | Keep both names; parent losartan is also active. Do not call it the only active form. |
| blood pressure starts to fall within a week; full effect 3–6 weeks | empieza a bajar durante la primera semana; efecto completo puede tardar de 3 a 6 semanas | time course of pressure response, not time to outcome-trial benefit | Do not promise an individual onset. |
| kidney function and potassium | función renal y potasio | renal and electrolyte safety tests | Keep both; avoid implying potassium is administered by the tablet in a clinically meaningful dose. |
| harm or kill an unborn baby | dañar o causar la muerte del bebé en desarrollo | boxed fetal injury/death | Do not soften to a vague “may be unsafe.” Check preferred non-stigmatizing regional wording. |
| allergy to any component | alergia a cualquiera de sus componentes | product hypersensitivity contraindication | A history of unrelated allergy is not automatically the same claim. |
| aliskiren with diabetes | aliskirén si usted tiene diabetes | coadministration contraindicated in diabetes | Keep condition and concurrent use together. |
| report pregnancy right away | comuníquese de inmediato | urgent contact and pregnancy care | Preserve label's “discontinue as soon as detected” alongside prompt professional contact; no personalized dose or replacement advice. |
| 2–4 weeks in KDIGO | entre 2 y 4 semanas | guideline monitoring window after start/increase, risk-adjusted | Do not present as a universal patient schedule. |
Back-translation of the Spanish introduction for meaning check: “Losartan blocks the AT₁ receptor, like a switch a hormone uses to narrow blood vessels. The body also produces an active form called EXP3174 (E-3174), which helps block the receptor. Vessels can relax, and signals regulating salt in the kidneys change. Blood pressure begins to fall in the first week; full effect may take 3–6 weeks. Blood tests check kidney function and potassium. The highlighted warning says the drug can harm or kill a developing baby. The label prohibits use with allergy to any ingredient, or with aliskiren if the person has diabetes. Discuss these risks with the care team.” No English clinical claim is intentionally added in this paragraph. The safety box separately states the label-directed urgent pregnancy action.
Publication QA and unresolved review
- [VERIFY: compare every Spanish sentence against the frozen English copy and current Cozaar label immediately before publication; any English clinical edit reopens translation QA.]
- [VERIFY: a native Spanish-speaking qualified health professional checks clinical meaning, urgency, contraindication scope, country-neutral terms and teach-back comprehension. Record name, credentials, review date and exact version only after review.]
- [VERIFY: patient reading level and comprehension with representative Spanish readers; automated readability scores alone do not validate comprehension.]
- [VERIFY: Spanish links, accents, AT₁ subscript, caption timing, screen-reader pronunciation, mobile wrapping and language metadata in a built page.]
- [FOUNDER TO SUPPLY: actual native Spanish-speaking health-professional reviewer and documented review outcome.]
This file is a local draft only. It does not represent a live edit, published translation or completed clinical review.